ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri - Pharmaceutical Technology

As the first-to-market DPP-1 inhibitor in the respiratory field, Brinsupri is on course to become the standard of care in bronchiectasis treatment. As the first-to-market DPP-1 inhibitor, Brinsupri is on course to become the standard of care in bronchiectasis treatment. Since Brinsupri’s approval, Insmed has been at the forefront of non-cystic fibrosis bronchiectasis (NCFB), supporting programs to increase disease awareness and to improve clinical outcomes in this disease space. Credit: [U.P.SD]/Shutterstock.com At the 2026 American Thoracic Society (ATS) international conference, Insmed’s presence featured a strong focus on Brinsupri (brensocatib), the first-to-market therapy for non-cystic fibrosis bronchiectasis (NCFB) and first-in-class dipeptidyl…

Source: Pharmaceutical Technology